Mitotane serum level analysis; Good agreement between two different assays

Clinical Endocrinology

Volumn 73, Issue 2, 2010, Pages 271-272

  Hermsen, I G C ^a   Den Hartigh, J ^b   Haak, H R ^a  

^a MÁXIMA MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; MITOTANE; STREPTOZOCIN;

ADRENAL CORTEX CARCINOMA; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DETERMINATION; GAS LIQUID CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LETTER; PRIORITY JOURNAL;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; BLOOD CHEMICAL ANALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; LABORATORIES, HOSPITAL; MITOTANE; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS;

EID: 77954876833     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2010.03787.x     Document Type: Letter

References (6)

1. Terzolo, M., Angeli, A., Fassnacht, M. et al. (2007) Adjuvant mitotane treatment for adrenocortical carcinoma. New England Journal of Medicine 356, 2372 2380.
2. Bergenstal, D.M., Hertz, R., Lipsett, M.B. et al. (1960) Chemotherapy of adrenocortical cancer with o,p'-DDD. Annals of Internal Medicine, 53, 672.
3. Moolenaar, A.J., van, S.H., van Seters, A.P. et al. (1981) Blood levels of o,p'-DDD following administration in various vehicles after a single dose and during long-term treatment. Cancer Chemotherapy and Pharmacology 7, 51 54.
4. van Slooten, H., Moolenaar, A.J., van Seters, A.P. et al. (1984) The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring. European Journal of Cancer and Clinical Oncology 20, 47 53.
5. Baudin, E., Pellegriti, G., Bonnay, M. et al. (2001) Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92, 1385 1392.
6. Haak, H.R., Hermans, J., van de Velde, C.J. et al. (1994) Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. British Journal of Cancer 69, 947 951.